stockrow
Friday 6 November 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million.
- Revenue
- −85.5%
- EPS
- −30.4%
- Free cash flow
- −92.8%
- Total debt
- −83.6%
Quarter to September 2026, against a year earlier
5.41
0.13
−2.35%
Follow BIOA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 9 | 9 | — | 8 | 15 | 3 | (32.1%) | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | 100.00 | — | ||||||
| EBT | — | — | — | — | — | — | — | (64) | (71) | (81) | (108) | +12.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (896.11) | (1,253.60) | (896.1) pt | ||||||
| Net income | — | — | — | — | — | — | — | (64) | (71) | (81) | (108) | +12.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.25 | 0.19 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (38.17) | (6.63) | (2.24) | (2.55) | (75.8%) | ||||||
| Cash flow | — | — | — | — | — | — | — | (22.33) | (4.80) | (2.27) | (2.23) | (68.1%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.10) | (0.03) | (4.33) | (3.38) | +560.4% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (22.43) | (4.84) | (6.60) | (5.61) | (45.8%) | ||||||
| Book value | — | — | — | — | — | — | — | (103.66) | 30.12 | 7.57 | 7.55 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 2 | 11 | 36 | 42 | +363.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 52.85 | 29.58 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 1.75 | 0.73 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 22.01 | (7.23) | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (0.84) | 0.24 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (37) | (52) | (82) | (103) | +47.8% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | (155) | (155) | +2,960.3% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (38) | (52) | (237) | (258) | +151.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (33) | 329 | 267 | 276 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | (11) | (346) | (278) | (319) | +408.8% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | (173) | 323 | 272 | 346 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (37.02) | (24.68) | (32.05) | (24.7) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (21.75) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | (94.98) | (27.09) | (34.56) | (27.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 60 | 64 | 62 | — | +1.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.15 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
BioAge Labs, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACB Aurora Cannabis Inc. | $341.2M | — (loss-making) | — (loss-making) | −31.15% (below 0%: shrinking) | n/m | −293.56% (below 0%: shrinking) | 52.73% | (12.92%) | Compare |
| EBS Emergent Biosolutions Inc. | $300.8M | — (loss-making) | — (loss-making) | −52.40% (below 0%: shrinking) | n/m | +1,892.98% (above 0%: growing) | 26.55% | (33.91%) | Compare |
| CGC Canopy Growth Corporation | $283.5M | — (loss-making) | — (loss-making) | +12.41% (above 0%: growing) | n/m | −117.60% (below 0%: shrinking) | 27.40% | (27.24%) | Compare |
| ANIK Anika Therapeutics Inc. | $258.7M | — (loss-making) | 599× | +15.56% (above 0%: growing) | n/m | +61.58% (above 0%: growing) | 65.15% | 9.06% | Compare |
| BIOA BioAge Labs, Inc. | $254.3M | — (loss-making) | — (loss-making) | −85.49% (below 0%: shrinking) | n/m | −92.81% (below 0%: shrinking) | 100.00% | (12,554.03%) | |
| LFCR Lifecore Biomedical, Inc. | $242.6M | — (loss-making) | — (loss-making) | −18.60% (below 0%: shrinking) | n/m | +27,684.00% (above 0%: growing) | 26.96% | (3.53%) | Compare |
| SIGA Siga Technologies Inc. | $213.4M | — (loss-making) | 60.8× | −49.45% (below 0%: shrinking) | −66.00% (below 0%: shrinking) | −75.95% (below 0%: shrinking) | 57.17% | 33.91% | Compare |
| ADCT ADC Therapeutics SA | $209.4M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| GLAS Glass House Brands Inc. | $172.7M | — (loss-making) | — (loss-making) | −1.24% (below 0%: shrinking) | n/m | −123.36% (below 0%: shrinking) | 33.54% | (6.37%) | Compare |
| Median of peers | $250.6M | — | — | −9.92% | — | −12.48% | 43.14% | (9.65%) |
Pay and ownership Proxy statement filed 21 April 2026
Ownership
Directors and executive officers, together
17.55%
Entities affiliated with Cormorant
7.41%
Entities affiliated with Andreessen Horowitz
7.28%
Kristen Fortney
5.64%
James Healy
5.27%
Entities affiliated with Sofinnova Venture Partners XI, L.P.
5.19%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement